Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.56 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.46 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516799 | 0.99 | ABL1 (0.58) | ABL1RIN1GPR119TGFBR1MEN1 | |
| SCHEMBL4511902 | 0.92 | GPR119 (0.56) | ABL1RIN1GPR119TGFBR1MEN1 | |
| SCHEMBL4518799 | 0.90 | GPR119 (0.52) | ABL1RIN1GPR119TGFBR1MEN1 | |
| SCHEMBL4515215 | 0.89 | GPR119 (0.51) | ABL1RIN1GPR119TGFBR1MEN1 | |
| SCHEMBL4516328 | 0.88 | GPR119 (0.54) | ABL1RIN1GPR119TGFBR1MEN1 | |
| SCHEMBL4516324 | 0.88 | GPR119 (0.54) | ABL1RIN1GPR119TGFBR1MEN1 | |
| SCHEMBL4504053 | 0.88 | GPR119 (0.60) | GPR119TGFBR1MEN1KMT2ACYP2C19 | |
| SCHEMBL4515782 | 0.87 | GPR119 (0.74) | GPR119TGFBR1MEN1KMT2ACYP2C19 | |
| SCHEMBL7366692 | 0.85 | GPR119 (0.59) | GPR119TGFBR1 | |
| SCHEMBL4524071 | 0.85 | GPR119 (0.51) | ABL1RIN1GPR119TGFBR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | GPR119, GCGR, GPBAR1 | ABL1 3033/4885RIN1 1624/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.